Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sina Bavari

Showing results (1-10 of 298) with videos related to

Pageof 30
Sort By:
Trends in Microbiology|December 24, 2014
A race for an Ebola vaccine: promises and obstaclesChristopher L Cooper, Sina Bavari
The Lancet. Infectious Diseases|March 23, 2020
Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the fieldSina Bavari, Patrick L Iversen
Viruses|October 14, 2011
Correlates of immunity to filovirus infectionSteven B Bradfute, Sina Bavari
Expert Opinion on Drug Discovery|March 9, 2019
Broad-spectrum coronavirus antiviral drug discoveryAllison L Totura, Sina Bavari
The Lancet. Infectious Diseases|March 4, 2017
Asymptomatic Ebola virus infections-myth or reality?Jens H Kuhn, Sina Bavari
The Lancet. Infectious Diseases|March 27, 2021
Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?Patrick L Iversen, Sina Bavari
Expert Opinion on Drug Discovery|May 26, 2015
Animal models for ebolavirus countermeasures discovery: what defines a useful model?Amy C Shurtleff, Sina Bavari
The Lancet. Healthy Longevity|August 25, 2021
Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or olderPatrick L Iversen, Sina Bavari
The American Journal of Tropical Medicine and Hygiene|April 6, 2020
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19)Maryam Keshtkar-Jahromi, Sina Bavari
The Lancet. Infectious Diseases|February 6, 2021
Inactivated COVID-19 vaccines to make a global impactPatrick L Iversen, Sina Bavari
Pageof 30

Showing results (1-10 of 298) with videos related to

Sort By:
Pageof 30
Trends in Microbiology|December 24, 2014
A race for an Ebola vaccine: promises and obstaclesChristopher L Cooper, Sina Bavari
The Lancet. Infectious Diseases|March 23, 2020
Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the fieldSina Bavari, Patrick L Iversen
Viruses|October 14, 2011
Correlates of immunity to filovirus infectionSteven B Bradfute, Sina Bavari
Expert Opinion on Drug Discovery|March 9, 2019
Broad-spectrum coronavirus antiviral drug discoveryAllison L Totura, Sina Bavari
The Lancet. Infectious Diseases|March 4, 2017
Asymptomatic Ebola virus infections-myth or reality?Jens H Kuhn, Sina Bavari
The Lancet. Infectious Diseases|March 27, 2021
Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?Patrick L Iversen, Sina Bavari
Expert Opinion on Drug Discovery|May 26, 2015
Animal models for ebolavirus countermeasures discovery: what defines a useful model?Amy C Shurtleff, Sina Bavari
The Lancet. Healthy Longevity|August 25, 2021
Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or olderPatrick L Iversen, Sina Bavari
The American Journal of Tropical Medicine and Hygiene|April 6, 2020
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19)Maryam Keshtkar-Jahromi, Sina Bavari
The Lancet. Infectious Diseases|February 6, 2021
Inactivated COVID-19 vaccines to make a global impactPatrick L Iversen, Sina Bavari
Pageof 30